Eczema Is Visible. But What Exactly Are We Seeing? |
Look at an area of eczema-affected skin and the change may seem obvious. It may look redder. Darker. Lighter. Rougher. More irregular.
But from a research perspective, “it looks different” is only the beginning.
What exactly has changed?
Is the difference related to redness? Pigmentation? Skin texture? Surface morphology? Or several of these characteristics at the same time?
And when the appearance of the skin changes over time, do all of these characteristics evolve together?
Not necessarily.
A decrease in redness does not automatically mean that a pigmentary change has disappeared. An improvement in color does not necessarily tell us what happened to the skin surface. And an overall visual improvement does not reveal which individual characteristics changed, or by how much.
This makes the visible appearance of eczema particularly interesting to study.
Rather than treating it as a single visual outcome, researchers can look more closely at the different characteristics contributing to what we see, and how each one evolves over time.
Because eczema may be visible. But not every visible change tells the same story.
A Visible Color Change Isn't Necessarily Just Redness |
Redness is one of the most recognizable visible characteristics associated with eczema and other inflammatory skin conditions.
But skin color is complex.
What appears visually as a change in color can involve different chromophores within the skin. In particular, hemoglobin contributes to redness, while melanin contributes to pigmentation.
Why does that distinction matter?
Because a skin area that looks different from baseline may not simply be “more red” or “less red.”
During an inflammatory episode, redness may become more prominent. As it subsides, the appearance of the area can continue to evolve. Pigmentary changes may develop or remain visible even after redness has decreased.
So instead of asking only: “Has the redness improved?” a more detailed evaluation might ask: “What component of the skin color has actually changed?”
This is where objective color analysis becomes particularly interesting.
When Redness and Pigmentation Tell Different Stories |
Eczema can be associated with post-inflammatory pigmentary changes, including hyperpigmentation and hypopigmentation.
These changes may persist after active inflammation has improved, meaning that the visual evolution of an affected area is not necessarily linear.
For example:
Redness may decrease. Pigmentation may remain.
Visually, the skin may still look different from surrounding unaffected skin, but for a different reason.
This distinction is also important when considering the diversity of eczema presentation across different skin tones. Redness may not always appear as the bright red color traditionally associated with erythema, while pigmentary changes may be particularly noticeable.
For researchers, separating redness-related and pigmentation-related information can therefore provide a more precise understanding of what is contributing to a visible color change.
Color Is Only Part of the Story |
Eczema does not affect only how the skin looks in terms of color. It can also alter how the skin surface looks and feels.
Dryness, scaling, roughness and other surface changes can modify the skin's texture and morphology.
And this introduces a completely different type of information.
Color is primarily an optical characteristic.
Texture is a topographical characteristic.
A conventional photograph can show that the skin appears rough or irregular. But appearance alone does not tell us how the surface itself has changed.
This is where three-dimensional analysis becomes relevant.
From Visible Texture to Measurable Surface Topography |
Skin is not flat. Its surface contains elevations, depressions and fine structures that contribute to what we perceive visually as texture.
With 3D skin imaging, those surface characteristics can be represented and analyzed quantitatively.
Instead of simply documenting that eczema-affected skin appears rougher, researchers can investigate changes in skin texture and surface morphology.
The question shifts from:
“Does the skin look smoother?”
to:
“How has the skin surface changed?”
That distinction is important. One is an observation. The other opens the door to quantitative analysis.
Redness. Pigmentation. Texture. Three Different Types of Information. |
Now the visible complexity of eczema becomes clearer.
An affected area can present several characteristics at the same time:
REDNESS
→ Color-related information associated with hemoglobin
PIGMENTATION
→ Color-related information associated with melanin
TEXTURE
→ Topographical information related to the skin surface
They may appear together.
But they are not the same parameter, and they do not necessarily evolve in the same way. This is one of the reasons why objective eczema skin imaging can be valuable in research.
Rather than treating the appearance of affected skin as one global visual outcome, individual characteristics can be investigated separately.
When an Image Becomes Data with Antera 3D® from Miravex |
Photography is invaluable for documenting visible skin changes. But when the objective is to understand what changed, by how much, and over time, an image alone may not provide all the answers.
This is where quantitative skin imaging can take the evaluation further, transforming selected visible characteristics into measurable data.
For eczema-related research, this is particularly relevant because the characteristics we have discussed so far are not all the same.
Texture is topographical. Redness and pigmentation are color-related.
Antera 3D® from Miravex brings these complementary perspectives together in a single platform, combining patented 3D Skin Surface Reconstruction with Multispectral Imaging.
Skin texture is more than a visual impression. It is created by the elevations, depressions and irregularities that form the skin's surface topography.
Using patented 3D Skin Surface Reconstruction, Antera 3D® captures and reconstructs the skin surface in three dimensions, allowing its topographical characteristics to be analyzed quantitatively.
For eczema-related research, this means moving beyond simply observing that an affected area appears rougher or smoother.
Researchers can investigate how the skin surface and texture change over time, adding objective data to the visual assessment.
Texture Capture & Selected ROI
Skin color tells a different story.
Using Multispectral Imaging, Antera 3D® provides color-related information associated with key skin chromophores, including hemoglobin and melanin.
This allows two visually related, but biologically distinct, characteristics to be investigated separately:
REDNESS → Hemoglobin-related information
PIGMENTATION → Melanin-related information
That distinction can be particularly valuable when following eczema-affected skin over time.
A visible color change may reflect a decrease in redness, a change in pigmentation, or a combination of both. Rather than treating skin color as one overall visual outcome, multispectral analysis helps researchers determine which color-related characteristic is changing.
Redness Capture & Selected ROI
Pigmentation Capture & Selected ROI
Together, the two technologies provide complementary information from the same area of skin:
3D SKIN SURFACE RECONSTRUCTION → Texture & surface topography
MULTISPECTRAL IMAGING → Redness & pigmentation
One acquisition. Multiple visible characteristics.
From a Single Acquisition to Longitudinal Analysis |
Capturing different visible skin characteristics is valuable.
Following how they evolve over time can be even more informative.
In eczema-related research, redness, pigmentation and texture may not follow the same trajectory. A visible improvement at follow-up may therefore reflect changes in one characteristic, several characteristics, or each at a different rate.
With standardized acquisitions at baseline and subsequent study visits, eczema skin imaging can help researchers compare the same area over time and investigate these changes quantitatively.
Consider a simple study sequence: BASELINE → TREATMENT → FOLLOW-UP
3D surface analysis may reveal changes in skin texture.
Hemoglobin-related information may indicate changes associated with redness.
Melanin-related information may show that pigmentation is evolving differently or remains visible after other characteristics have changed.
Instead of reducing the outcome to a single before-and-after impression, longitudinal analysis can help answer a more precise question:
What changed, how much did it change, and when?
This ability to follow individual visible characteristics over time can provide valuable complementary endpoints for efficacy studies, clinical research and treatment evaluation.
Why Eczema Skin Imaging Matters Across Skin Research & Evaluation |
Eczema highlights a broader challenge in skin research:
How do you turn a visible skin change into objective, measurable evidence?
The question extends well beyond eczema and is highly relevant across the cosmetic, dermocosmetic, dermatological and aesthetic fields.
Whenever redness, pigmentation or texture is part of the outcome being evaluated, quantitative skin imaging can help researchers move from visual observation toward objective characterization and longitudinal comparison.
Cosmetic and dermocosmetic products increasingly address visible concerns such as redness, uneven skin tone, rough texture and sensitive-looking skin.
For researchers, a before-and-after photograph can document a visible difference.
Quantitative imaging can add another level of evidence by helping determine which characteristics changed and by how much.
Quantitative skin imaging can support multiple stages of product evaluation, from formulation development and efficacy testing to clinical studies and the substantiation of cosmetic and dermocosmetic claims.
For example, a product may be associated with a visible improvement in the overall appearance of the skin. But quantitative analysis can help investigate whether that difference is related primarily to surface texture, redness, pigmentation, or a combination of several parameters.
The image shows the result. The data help characterize it.
Visual examination and validated clinical assessments remain fundamental in dermatology.
Quantitative imaging can complement these approaches by providing image-derived endpoints for specific visible skin characteristics, allowing researchers to investigate redness, pigmentation and surface texture individually and compare their evolution across study visits.
The objective is not to replace clinical expertise or established scoring systems.
It is to add quantitative imaging endpoints that can strengthen the characterization of visible skin changes and support longitudinal research.
Redness, pigmentation and texture are also central to many aesthetic applications.
Topical regimens, chemical peels, lasers, energy-based procedures and other aesthetic interventions can influence skin color and surface characteristics, and these effects may evolve differently during the post-treatment period.
Quantitative skin imaging can support before-and-after evaluation by helping distinguish what is actually contributing to the visible change.
Has redness decreased?
Has pigmentation evolved?
Has surface texture changed?
Are several characteristics changing simultaneously?
Different applications can raise different questions. But the scientific principle remains the same:
Don't just document the difference. Identify and quantify what changed.
October's Eczema Awareness Month brings greater attention to a condition that can present very differently from one person to another.
For research, that diversity carries an important message: what we see deserves to be characterized carefully.
An affected area may change in color, surface appearance or both. Those characteristics may evolve together or follow different timelines.
And an overall visual improvement does not necessarily reveal which individual characteristic has changed.
This is why greater awareness can also encourage more objective and detailed approaches to evaluating eczema-affected skin.
By complementing clinical observation with quantitative methods, researchers can move beyond documenting that the skin looks different and investigate what is driving that difference.
For eczema skin imaging, this means distinguishing and following individual visible characteristics rather than treating the appearance of affected skin as a single outcome.
Awareness helps us recognize what we see.
Objective characterization helps us understand what is changing.
Eczema can present through multiple visible characteristics, and those characteristics do not necessarily change in the same way or at the same time.
This is where eczema skin imaging can take visual assessment further, transforming what researchers see into objective, quantitative scientific data.
With Antera 3D®, visible changes in eczema-affected skin can be captured, visualized and analyzed through complementary information on surface topography, texture, redness and pigmentation, while their evolution can be followed across successive acquisitions.
The goal is not to replace clinical assessment, but to complement it with quantitative, image-derived evidence that helps researchers characterize what is actually changing.
Because when eczema-affected skin looks different, don't just ask:
“Does it look better?” Ask: “What changed and what does the image reveal?”
Antera 3D®:
Image. Analyze. Quantify. Follow Visible Eczema Changes Over Time.
From Visible Change to Measurable Evidence.
Take Eczema Research Further with Antera 3D®.
Discover the Miravex Antera 3D® platform at Skinlabs and see how its unique combination of patented 3D skin surface reconstruction and multispectral analysis brings a new dimension to objective skin characterization. |
Antera 3D® has been used in clinical studies involving patients with atopic dermatitis to objectively assess and monitor visible skin characteristics associated with the condition and their evolution following treatment.
JAAD
Niemeyer-van der Kolk T, Buters TP, Krouwels L, Boltjes J, de Kam ML, van der Wall H, van Alewijk DCJG, van den Munckhof EHA, Becker MJ, Feiss G, Florencia EF, Prens EP, Moerland M, Burggraaf J, Rissmann R, van Doorn MBA. Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. J Am Acad Dermatol. 2022 Apr;86(4):854-862. doi: 10.1016/j.jaad.2020.08.132. Epub 2020 Oct 1. PMID: 33010325.
VESTNIK DERMATOLOGII I VENEROLOGII
Snarskaya E.S., Bratkovskaya A.V. Novel filagrinol-containing emollient // Vestnik dermatologii i venerologii. - 2022. - Vol. 98. - N. 5. - P. 65-89. doi: 10.25208/vdv1342
DERMATOLOGY PRACTICAL & CONCEPTUAL
Gkagkari P, Tagka A, Stratigos A, Karalis V, Kyritsi A, Vitsos A, Rallis MC. Differential Diagnosis of Irritant Versus Allergic Contact Dermatitis Based on Noninvasive Methods. Dermatol Pract Concept. 2024 Oct 30;14(4):e2024231. doi: 10.5826/dpc.1404a231. PMID: 39652964; PMCID: PMC11619931.
BIOENGINEERING (BASEL)
Vezakis IA, Lambrou GI, Kyritsi A, Tagka A, Chatziioannou A, Matsopoulos GK. Detecting Skin Reactions in Epicutaneous Patch Testing with Deep Learning: An Evaluation of Pre-Processing and Modality Performance. Bioengineering (Basel). 2023 Aug 3;10(8):924. doi: 10.3390/bioengineering10080924. PMID: 37627809; PMCID: PMC10451716.
BIOENGINEERING (BASEL)
Gilou SC, Tagka A, Lambrou GI, Papanastasiou E, Matsopoulos GK, Bamidis PD. Quantitative Evaluation of Patch Test Reactions Using a 3D Camera-Derived Features and Machine Learning: The Role of Temporal Dynamics. Bioengineering (Basel). 2026 Jul 16;13(7):818. doi: 10.3390/bioengineering13070818. PMID: 42510483; PMCID: PMC13404982.
Comments